Johnson & Johnson will pay $2.2 billion to settle charges that the company marketed drugs for unapproved uses and paid "kickbacks" to doctors and nursing homes, CNNMoney reported. The penalty, one of the country's largest health care-related settlements, involves the schizophrenia drugs Risperdal and Invega, and the heart failure drug Natrecor. The pharmaceutical company and two subsidiaries "lined their pockets at the expense of American taxpayers, patients and the private insurance industry," U.S. Attorney General Eric Holder said in a press release. Whistle-blowers in three states will collect $167.7 million under the False Claims Act. On Monday, Johnson & Johnson defended Risperdal "as safe and effective for its approved indications" and said two decades of research shows it is "an important treatment option for people with serious mental illness." Risperdal was approved by the Federal Drug Administration to treat schizophrenia but was marketed to doctors and nursing homes as a treatment for elderly patients with dementia.